Teva Pharmaceutical Industries 대차 대조표 상태
재무 상태 기준 확인 2/6
Teva Pharmaceutical Industries 의 총 주주 지분은 $6.4B 이고 총 부채는 $19.0B, 이는 부채 대 자기자본 비율을 297.3% 로 가져옵니다. 총자산과 총부채는 각각 $41.8B 및 $35.4B 입니다. Teva Pharmaceutical Industries 의 EBIT는 $3.7B 이며 이자보상배율은 4 입니다. $3.3B 의 현금 및 단기 투자금을 보유하고 있습니다.
주요 정보
297.3%
부채 비율
US$18.98b
부채
| 이자 보상 비율 | 4x |
| 현금 | US$3.32b |
| 주식 | US$6.38b |
| 총 부채 | US$35.37b |
| 총 자산 | US$41.76b |
최근 재무 상태 업데이트
Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?
Oct 21
Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Jul 12Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet
Mar 26These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way
Dec 11Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt
Sep 09Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load
Jun 06Recent updates
Why Investors Shouldn't Be Surprised By Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Low P/S
Nov 17Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt
Oct 23Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?
Oct 21Cheap Teva Stock Should Reward Patient Investors
Sep 09Teva's Transformation: From Generics Leader To Branded Drug Innovator
Aug 14Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 02Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs
Jul 26Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Jul 12Teva Pharmaceutical: Buy This Bargain Before It's Gone
Jun 07Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
May 14Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)
May 09Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet
Mar 26Teva Pharmaceutical Industries: Potential Outweighs Concerns
Mar 25Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities
Feb 26A Review Of Teva's Prospects
Feb 15Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry
Jan 07These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way
Dec 11Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)
Dec 08Teva: Deeply Undervalued FCF Machine
Nov 20Teva: Focus On Innovation And Growth Means The Times They Are A Changing
Sep 14Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt
Sep 09The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider
Aug 26Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain
Aug 02Teva Pharmaceutical: Lacking Capabilities For Strategic Investments
Jul 20Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence
Jun 15Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load
Jun 06Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Feb 20What To Expect From Teva Pharmaceutical In 2023 With A New CEO
Feb 15Can Teva Pharmaceutical's Q4 results bring positive surprise?
Feb 07Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment
Jan 19Tamiflu supplies released from national stockpile as nationwide shortage persists
Jan 12Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year
Dec 28Federal appeals court temporarily blocks generics of Vanda's Hetlioz by Teva, Apotex
Dec 16Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit
Nov 10재무 상태 분석
단기부채: TEVA 의 단기 자산 ( $12.3B )은 단기 부채( $13.8B ).
장기 부채: TEVA 의 단기 자산( $12.3B )은 장기 부채( $21.6B ).
부채 대 자본 내역 및 분석
부채 수준: TEVA 의 순부채 대 자기자본 비율( 245.3% )은 높음으로 간주됩니다.
부채 감소: TEVA 의 부채 대 자기자본 비율은 지난 5년간 180.5% 에서 297.3% 로 증가했습니다.
대차 대조표
현금 런웨이 분석
과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.
안정적인 현금 활주로: 수익성이 없는 TEVA 현재의 플러스 무료 현금 흐름 수준을 유지한다면 3년 이상 충분한 현금 활주로를 보유하고 있습니다.
예측 현금 활주로: TEVA 은(는) 수익성이 없지만 잉여 현금 흐름이 긍정적이고 매년 1.8 %씩 성장하기 때문에 3년 이상 충분한 현금 활주로를 보유하고 있습니다.